豪掷近5亿美元辉瑞(PFE.US)牵手中国biotech，加码在华减肥药市场

智通财经02-24

智通财经APP获悉，美国制药巨头辉瑞公司(PFE.US)与本土初创企业杭州先为达生物科技股份有限公司达成协议，以获得后者一款减肥疗法在中国的独家商业化权益，此举旨在强化其在高增长减肥市场的布局。根据一份声明，双方达成的交易涉及药物ecnoglutide。该药近期在中国获批用于治疗糖尿病，目前其用于减肥的适应症正处于监管审查阶段。先为达表示，这笔交易总额最高可达4.95亿美元，包括首付款和基于里程碑...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2613110762?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-24 14:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613110762","market":"fut","top_or_hot":-1,"title":"豪掷近5亿美元辉瑞(PFE.US)牵手中国biotech，加码在华减肥药市场","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，美国制药巨头辉瑞公司(PFE.US)与本土初创企业杭州先为达生物科技股份有限公司达成协议，以获得后者一款减肥疗法在中国的独家商业化权益，此举旨在强化其在高增长减肥市场的布局。根据一份声明，双方达成的交易涉及药物ecnoglutide。该药近期在中国获批用于治疗糖尿病，目前其用于减肥的适应症正处于监管审查阶段。先为达表示，这笔交易总额最高可达4.95亿美元，包括首付款和基于里程碑...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1406590.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>豪掷近5亿美元辉瑞(PFE.US)牵手中国biotech，加码在华减肥药市场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n豪掷近5亿美元辉瑞(PFE.US)牵手中国biotech，加码在华减肥药市场\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-24 14:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1406590.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，美国制药巨头辉瑞公司(PFE.US)与本土初创企业杭州先为达生物科技股份有限公司达成协议，以获得后者一款减肥疗法在中国的独家商业化权益，此举旨在强化其在高增长减肥市场的布局。根据一份声明，双方达成的交易涉及药物ecnoglutide。该药近期在中国获批用于治疗糖尿病，目前其用于减肥的适应症正处于监管审查阶段。先为达表示，这笔交易总额最高可达4.95亿美元，包括首付款和基于里程碑...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1406590.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1057294990.SGD","symbol_name":"Blackrock World Healthscience A2 SGD-H","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1406590.html","article_id":"2613110762","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613110762","pubTimestamp":1771916204,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，美国制药巨头辉瑞公司与本土初创企业杭州先为达生物科技股份有限公司达成协议，以获得后者一款减肥疗法在中国的独家商业化权益，此举旨在强化其在高增长减肥市场的布局。该药近期在中国获批用于治疗糖尿病，目前其用于减肥的适应症正处于监管审查阶段。辉瑞一直大力追赶在减肥药领域的领先者。辉瑞正寻求在后疫情时代进行业务重建。在中国减肥药市场，辉瑞将直面全球制药巨头及信达生物等本土竞争对手的挑战。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","PFE":"辉瑞","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4568":"美国抗疫概念","BK4599":"减肥药","BK4588":"碎股","BK4550":"红杉资本持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4007":"制药","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0234572021.USD":"高盛美国核心股票组合Acc","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4581":"高盛持仓","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4592":"伊斯兰概念","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC"},"translate_title":"Spending nearly US $500 million, Pfizer (PFE.US) joins hands with Chinese biotech to increase its investment in China's diet drug market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.96},"content_text":"智通财经APP获悉，美国制药巨头辉瑞公司(PFE.US)与本土初创企业杭州先为达生物科技股份有限公司达成协议，以获得后者一款减肥疗法在中国的独家商业化权益，此举旨在强化其在高增长减肥市场的布局。根据一份声明，双方达成的交易涉及药物ecnoglutide。该药近期在中国获批用于治疗糖尿病，目前其用于减肥的适应症正处于监管审查阶段。先为达表示，这笔交易总额最高可达4.95亿美元，包括首付款和基于里程碑的后续付款，但未披露具体细节。辉瑞一直大力追赶在减肥药领域的领先者。辉瑞中国区总裁在声明中表示，该合作\"加速了辉瑞在代谢领域的长期战略布局，以满足中国患者日益增长的需求\"。他指出，肥胖影响着中国14.1%的成年人，并且已被列为政府\"健康中国\"行动的优先事项。辉瑞正寻求在后疫情时代进行业务重建。由于许多核心产品面临更激烈的竞争，且其最初进军减肥药市场的尝试受挫，该公司面临寻找新收入来源的压力。与先为达的合作亦有望提振辉瑞的中国业务。据了解，截至2024年，中国业务占辉瑞总收入的4%，但在过去几年中经历了多轮重组。在中国减肥药市场，辉瑞将直面全球制药巨头及信达生物等本土竞争对手的挑战。先为达的ecnoglutide与诺和诺德的司美格鲁肽(Ozempic)作用机理相似，均通过模拟一种名为胰高血糖素样肽-1(GLP-1)的天然激素来调节血糖和抑制食欲。但该公司认为，该药物略有不同的结构使其比其他GLP-1受体激动剂更有效、更安全。在一项后期研究中，ecnoglutide实现了与礼来公司的替尔泊肽(Zepbound)相媲美的减重效果。根据与辉瑞的协议，先为达仍将负责该药物的开发、注册、生产和供应。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613110762","isCrawlerRequest":true}